Vectans Pharma is a European-based pharmaceutical company with a primary focus to target unmet needs in patients with oral pathologies through the acquisition and worldwide commercial development of innovative targeted therapeutics.
Our current portfolio includes Sitavig^® and Loramyc^®, 2 products approved by FDA and several authorities in Europe, and 1 proprietary innovative galenic technology : Lauriad^®.